Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Kinetic properties of carbohydrate-lectin interactions: FimH antagonists.

Scharenberg M, Jiang X, Pang L, Navarra G, Rabbani S, Binder F, Schwardt O, Ernst B.

ChemMedChem. 2014 Jan;9(1):78-83. doi: 10.1002/cmdc.201300349. Epub 2013 Dec 2.

PMID:
24357503
2.

FimH antagonists: structure-activity and structure-property relationships for biphenyl α-D-mannopyranosides.

Pang L, Kleeb S, Lemme K, Rabbani S, Scharenberg M, Zalewski A, Schädler F, Schwardt O, Ernst B.

ChemMedChem. 2012 Aug;7(8):1404-22. doi: 10.1002/cmdc.201200125. Epub 2012 May 29.

PMID:
22644941
3.

Target Selectivity of FimH Antagonists.

Scharenberg M, Schwardt O, Rabbani S, Ernst B.

J Med Chem. 2012 Nov 26;55(22):9810-6. doi: 10.1021/jm3010338. Epub 2012 Nov 1.

PMID:
23088608
4.

The tyrosine gate as a potential entropic lever in the receptor-binding site of the bacterial adhesin FimH.

Wellens A, Lahmann M, Touaibia M, Vaucher J, Oscarson S, Roy R, Remaut H, Bouckaert J.

Biochemistry. 2012 Jun 19;51(24):4790-9. doi: 10.1021/bi300251r. Epub 2012 Jun 7.

PMID:
22657089
5.

Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin.

Bouckaert J, Berglund J, Schembri M, De Genst E, Cools L, Wuhrer M, Hung CS, Pinkner J, Slättegård R, Zavialov A, Choudhury D, Langermann S, Hultgren SJ, Wyns L, Klemm P, Oscarson S, Knight SD, De Greve H.

Mol Microbiol. 2005 Jan;55(2):441-55.

6.

A flow cytometry-based assay for screening FimH antagonists.

Scharenberg M, Abgottspon D, Cicek E, Jiang X, Schwardt O, Rabbani S, Ernst B.

Assay Drug Dev Technol. 2011 Oct;9(5):455-64. doi: 10.1089/adt.2010.0357. Epub 2011 Jun 15.

PMID:
21675870
7.

Expression of the carbohydrate recognition domain of FimH and development of a competitive binding assay.

Rabbani S, Jiang X, Schwardt O, Ernst B.

Anal Biochem. 2010 Dec 15;407(2):188-95. doi: 10.1016/j.ab.2010.08.007. Epub 2010 Aug 10.

PMID:
20705050
8.

Interdomain interaction in the FimH adhesin of Escherichia coli regulates the affinity to mannose.

Aprikian P, Tchesnokova V, Kidd B, Yakovenko O, Yarov-Yarovoy V, Trinchina E, Vogel V, Thomas W, Sokurenko E.

J Biol Chem. 2007 Aug 10;282(32):23437-46. Epub 2007 Jun 13.

9.

Positively selected FimH residues enhance virulence during urinary tract infection by altering FimH conformation.

Schwartz DJ, Kalas V, Pinkner JS, Chen SL, Spaulding CN, Dodson KW, Hultgren SJ.

Proc Natl Acad Sci U S A. 2013 Sep 24;110(39):15530-7. doi: 10.1073/pnas.1315203110. Epub 2013 Sep 3.

10.

Uroplakin Ia is the urothelial receptor for uropathogenic Escherichia coli: evidence from in vitro FimH binding.

Zhou G, Mo WJ, Sebbel P, Min G, Neubert TA, Glockshuber R, Wu XR, Sun TT, Kong XP.

J Cell Sci. 2001 Nov;114(Pt 22):4095-103.

11.

Comparative structure-function analysis of mannose-specific FimH adhesins from Klebsiella pneumoniae and Escherichia coli.

Stahlhut SG, Tchesnokova V, Struve C, Weissman SJ, Chattopadhyay S, Yakovenko O, Aprikian P, Sokurenko EV, Krogfelt KA.

J Bacteriol. 2009 Nov;191(21):6592-601. doi: 10.1128/JB.00786-09. Epub 2009 Sep 4.

12.

The affinity of the FimH fimbrial adhesin is receptor-driven and quasi-independent of Escherichia coli pathotypes.

Bouckaert J, Mackenzie J, de Paz JL, Chipwaza B, Choudhury D, Zavialov A, Mannerstedt K, Anderson J, Piérard D, Wyns L, Seeberger PH, Oscarson S, De Greve H, Knight SD.

Mol Microbiol. 2006 Sep;61(6):1556-68. Epub 2006 Aug 23.

13.

Development of an aggregation assay to screen FimH antagonists.

Abgottspon D, Rölli G, Hosch L, Steinhuber A, Jiang X, Schwardt O, Cutting B, Smiesko M, Jenal U, Ernst B, Trampuz A.

J Microbiol Methods. 2010 Sep;82(3):249-55. doi: 10.1016/j.mimet.2010.06.015. Epub 2010 Jul 8.

PMID:
20620174
14.

Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 complex.

Wellens A, Garofalo C, Nguyen H, Van Gerven N, Slättegård R, Hernalsteens JP, Wyns L, Oscarson S, De Greve H, Hultgren S, Bouckaert J.

PLoS One. 2008 Apr 30;3(4):e2040. doi: 10.1371/journal.pone.0002040. Erratum in: PLoS ONE. 2008;3(6). doi: 10.1371/annotation/ea59d179-0a71-4836-86f0-8d375f5df089.

15.

Type 1 fimbrial adhesin FimH elicits an immune response that enhances cell adhesion of Escherichia coli.

Tchesnokova V, Aprikian P, Kisiela D, Gowey S, Korotkova N, Thomas W, Sokurenko E.

Infect Immun. 2011 Oct;79(10):3895-904. doi: 10.1128/IAI.05169-11. Epub 2011 Jul 18.

16.

Molecular variations in Klebsiella pneumoniae and Escherichia coli FimH affect function and pathogenesis in the urinary tract.

Rosen DA, Pinkner JS, Walker JN, Elam JS, Jones JM, Hultgren SJ.

Infect Immun. 2008 Jul;76(7):3346-56. doi: 10.1128/IAI.00340-08. Epub 2008 May 12.

17.

Human Urine Decreases Function and Expression of Type 1 Pili in Uropathogenic Escherichia coli.

Greene SE, Hibbing ME, Janetka J, Chen SL, Hultgren SJ.

MBio. 2015 Jun 30;6(4):e00820. doi: 10.1128/mBio.00820-15.

18.

Allosteric coupling in the bacterial adhesive protein FimH.

Rodriguez VB, Kidd BA, Interlandi G, Tchesnokova V, Sokurenko EV, Thomas WE.

J Biol Chem. 2013 Aug 16;288(33):24128-39. doi: 10.1074/jbc.M113.461376. Epub 2013 Jul 2.

19.

FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation.

Klein T, Abgottspon D, Wittwer M, Rabbani S, Herold J, Jiang X, Kleeb S, Lüthi C, Scharenberg M, Bezençon J, Gubler E, Pang L, Smiesko M, Cutting B, Schwardt O, Ernst B.

J Med Chem. 2010 Dec 23;53(24):8627-41. doi: 10.1021/jm101011y. Epub 2010 Nov 24.

PMID:
21105658
20.

Differential stability and trade-off effects of pathoadaptive mutations in the Escherichia coli FimH adhesin.

Weissman SJ, Beskhlebnaya V, Chesnokova V, Chattopadhyay S, Stamm WE, Hooton TM, Sokurenko EV.

Infect Immun. 2007 Jul;75(7):3548-55. Epub 2007 May 14. Erratum in: Infect Immun. 2009 Apr;77(4):1720.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk